Dr. Evangelia Fouka
G. Papanikolaou General Hospital, Thessaloníki, Kentrikí Makedonía, Greece
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
13Years (2014-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications7 November 2024 in Journal of Allergy and Clinical Immunology
Journal Article
Kelly DomvriITIoanna Tsiouprou
Ioanna Tsiouprou
Petros BakakosPSPaschalis Steiropoulos
Paschalis Steiropoulos
KKKonstantinos Katsoulis
Konstantinos Katsoulis
KPKonstantinos Porpodis
Konstantinos Porpodis
+10
Journal Article
Anastasia Papaporfyriou
Konstantinos BartziokasDGDaniela Gompelmann
Daniela GompelmannMIMarco Idzko
Marco IdzkoEvangelia FoukaAPAndriana I Papaioannou
Andriana I Papaioannou +3
Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients.
Journal Article
Evangelia FoukaAPAndriana I Papaioannou
Andriana I PapaioannouGHGeorgios Hillas
Georgios Hillas
Paschalis SteiropoulosThe term asthma-COPD overlap (ACO) has been used to identify a heterogeneous condition in which patients present with airflow limitation that is not completely reversible and clinical and inflammatory features of both asthma and chronic obstructive pulmonary disease (COPD). ACO diagnosis may be difficult in clinical practice, while controversy still exists regarding its definition, pathophysiology, and impact. Patients with ACO experience a greater disease burden compared to patients with asthma or COPD alone, but in contrast they show better response to inhaled corticosteroid treatment than other COPD phenotypes. Current management recommendations focus on defining specific and measurable treatable clinical traits, according to disease phenotypes and underlying biological mechanisms for every single patient. In this publication, we review the current knowledge on definition, pathophysiology, clinical characteristics, and management options of ACO.
Journal Article
Konstantinos PorpodisITIoanna Tsiouprou
Ioanna TsiouprouAAApostolos Apostolopoulos
Apostolos ApostolopoulosPNPOLYXENI NJTONTSI
POLYXENI NJTONTSIEvangelia FoukaKelly Domvri +2
Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic agents have been developed towards a personalized approach to asthma management. This review will focus on different eosinophilic phenotypes and Th2-associated endotypes with eosinophilic inflammation. Additionally, airway remodeling is analyzed as a key feature of asthmatic eosinophilic endotypes. In addition, evidence of biomarkers is examined with a predictive value to identify patients with severe, uncontrolled asthma who may benefit from new treatment options. Finally, there will be a discussion on the results from clinical trials regarding severe eosinophilic asthma and how the inhibition of the eosinophilic pathway by targeted treatments has led to the reduction of recurrent exacerbations.
14 July 2014 in Lung
Journal Article
Evangelia FoukaELEleftheria Lamprianidou
Eleftheria Lamprianidou
KAKonstantinos Arvanitidis
Konstantinos Arvanitidis
EFEirini Filidou
Eirini FilidouGKGeorge Kolios
George KoliosDBDEMOSTHENES BOUROS BOUROS
DEMOSTHENES BOUROS BOUROS +4
26 September 2022 in Frontiers in Medicine
Journal Article
Evangelia FoukaKDKalliopi Domvri
Kalliopi Domvri
FGFoteini Gkakou
Foteini Gkakou
MAMaria Alevizaki
Maria Alevizaki
PSPaschalis Steiropoulos
Paschalis Steiropoulos
Konstantinos Porpodis +1
Contemporary asthma management requires a proactive and individualized approach, combining precision diagnosis and personalized treatment. The introduction of biologic therapies for severe asthma to everyday clinical practice, increases the need for specific patient selection, prediction of outcomes and monitoring of these costly and long-lasting therapies. Several biomarkers have been used in asthma in disease identification, prediction of asthma severity and prognosis, and response to treatment. Novel advances in the area of personalized medicine regarding disease phenotyping and endotyping, encompass the development and application of reliable biomarkers, accurately quantified using robust and reproducible methods. The availability of powerful omics technologies, together with integrated and network-based genome data analysis, and microbiota changes quantified in serum, body fluids and exhaled air, will lead to a better classification of distinct phenotypes or endotypes. Herein, in this review we discuss on currently used and novel biomarkers for the diagnosis and treatment of asthma.
About Me
Consultant in Pulmonary Medicine at the Pulmonary Department of the Aristotle University of Thessaloniki
General Hospital "G. Papanikolaou", Thessaloniki, Greece
PhD in Medicine on "The Immonomodulating Effects of Clarithromycin in Patients with Bronchiectasis", 3/2010–11/2014
Research Grant of the Hellenic Thoracic Society for a research work with the title "Exploration
of the immunomodulating effects of clarithromycin in patients with bronchiectasis using
exhaled breath condensate, blood, and sputum specimens" (2010).
Research Fellow in the Pulmonary Clinic of Democritus University of Thrace, under the
Supervision of Prof. D. Bouros (2010–2014).
Clinical and Research Fellow in Interventional Bronchoscopy and Interstitial Lung Diseases, Respiratory Department of Morgagni-Pierantoni Hospital, Forli, Italy (1/2/2020–9/3/2020).
Master of Science in Management of Public Health Care (2020, Neapolis University Pafos)
27 publications in Greek and international peer-reviewed journals
Head of the Asthma Group of the Hellenic Thoracic Society (2021–2023)
reviewer in 10 scientific journals.
140 presentations in Greek and international conferences
60 lectures in Greek conferences and seminars
Chairman of round tables in Greek and international congresses
Participation as a speaker and trainer in the postgraduate courses of the Thoracic Association
of Northern Greece and of the Hellenic Thoracic Society, continuously since 2005.